S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Mind Medicine (MindMed) Stock Forecast, Price & News

-0.01 (-1.91%)
(As of 06/29/2022 08:58 PM ET)
Today's Range
50-Day Range
52-Week Range
1.64 million shs
Average Volume
3.83 million shs
Market Capitalization
$281.77 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive MNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.

MNMD Stock Forecast (MarketRank)

Overall MarketRank

1.87 out of 5 stars

Medical Sector

726th out of 1,432 stocks

Medicinals & Botanicals Industry

4th out of 23 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

MNMD Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Company Calendar

Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$-93.04 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
0.36 per share


Free Float
Market Cap
$281.77 million
Not Optionable

Mind Medicine (MindMed) Frequently Asked Questions

Should I buy or sell Mind Medicine (MindMed) stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mind Medicine (MindMed) stock.
View analyst ratings for Mind Medicine (MindMed)
or view top-rated stocks.

What is Mind Medicine (MindMed)'s stock price forecast for 2022?

2 equities research analysts have issued 12-month price objectives for Mind Medicine (MindMed)'s shares. Their MNMD stock forecasts range from 7.00 to 10.00. On average, they predict Mind Medicine (MindMed)'s share price to reach 8.50 in the next twelve months. This suggests a possible upside of 1,174.4% from the stock's current price.
View analysts' price targets for Mind Medicine (MindMed)
or view top-rated stocks among Wall Street analysts.

How has Mind Medicine (MindMed)'s stock performed in 2022?

Mind Medicine (MindMed)'s stock was trading at 1.38 on January 1st, 2022. Since then, MNMD shares have decreased by 51.7% and is now trading at 0.67.
View the best growth stocks for 2022 here

Who are Mind Medicine (MindMed)'s key executives?

Mind Medicine (MindMed)'s management team includes the following people:
  • Mr. Robert Barrow, CEO & Director (Age 33, Pay $708.41k)
  • Dr. Miriam Halperin Wernli Ph.D., Exec. Pres & Director (Age 69, Pay $552.46k)
  • Dr. Daniel Rollings Karlin M.A., M.D., Chief Medical Officer (Age 42, Pay $493.21k)
  • Dr. Scott M. Freeman, Co-Founder & Clinical Advisor (Age 65)
  • Mr. Leonard Latchman, Co-founder
  • Mr. Schond L. Greenway, Chief Financial Officer (Age 50)
  • Ms. Carrie F. Liao CPA, CGMA, VP, Corp. Controller & Accounting Principal
  • Ms. Wong Hu J.D., Chief Legal Officer & Corp. Sec. (Age 52)
  • Dr. Francois P. Lilienthal M.B.A., M.D., Chief Commercial Officer

What is Mind Medicine (MindMed)'s stock symbol?

Mind Medicine (MindMed) trades on the NASDAQ under the ticker symbol "MNMD."

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mind Medicine (MindMed)'s stock price today?

One share of MNMD stock can currently be purchased for approximately 0.67.

How much money does Mind Medicine (MindMed) make?

Mind Medicine (MindMed) (NASDAQ:MNMD) has a market capitalization of $281.77 million. The company earns $-93.04 million in net income (profit) each year or -0.23 on an earnings per share basis.

How many employees does Mind Medicine (MindMed) have?

Mind Medicine (MindMed) employs 41 workers across the globe.

How can I contact Mind Medicine (MindMed)?

The official website for Mind Medicine (MindMed) is www.mindmed.co. The company can be reached via phone at 650-208-2454 or via email at [email protected].

This page (NASDAQ:MNMD) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.